Delcath Systems Inc (DCTH)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $714.89M
Last updated: Nov 17, 2026 at 11:03 AM ET
Delcath Systems Inc (DCTH) Earnings: Report Dates and Results
Delcath Systems (DCTH) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Delcath Systems reported EPS of $0.17, above the -$0.10 estimate. It beat the EPS estimate in each of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
DCTH has an expected report date of Feb 22, 2027.
DCTH Earnings Call
The latest DCTH earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 26 quarters below that had an estimate, DCTH beat 17, missed 7 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $35.10M, up 70.7% from $20.56M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.17 | -$0.10 | -$0.13 - -$0.04 | +270.00% | Beat | +750.0% | 4 | 0 up, 1 down | Nov 9, 2026 | $35.10M |
| Jun 30, 2026 | $0.07 | -$0.16 | -$0.16 - -$0.05 | +143.75% | Beat | 0.0% | 2 | 0 up, 3 down | Aug 6, 2026 | $29.13M |
| Mar 31, 2026 | -$0.03 | -$0.09 | -$0.14 - -$0.01 | +66.67% | Beat | -200.0% | 5 | 0 up, 3 down | May 7, 2026 | $24.99M |
| Dec 31, 2025 | -$0.05 | -$0.06 | -$0.09 - $0.04 | +16.67% | Beat | N/A | 5 | 0 up, 0 down | Feb 26, 2026 | $20.73M |
| Sep 30, 2025 | $0.02 | -$0.09 | -$0.09 - -$0.09 | +122.22% | Beat | -66.7% | 1 | 0 up, 1 down | Nov 4, 2025 | $20.56M |
| Jun 30, 2025 | $0.07 | $0.03 | $0.00 - $0.07 | +133.33% | Beat | N/A | 5 | 0 up, 1 down | Aug 6, 2025 | $24.16M |
| Mar 31, 2025 | $0.03 | $0.03 | -$0.04 - $0.10 | +15.38% | Beat | N/A | 5 | 0 up, 0 down | May 8, 2025 | $19.78M |
| Dec 31, 2024 | -$0.11 | $0.01 | -$0.10 - $0.09 | N/A | N/A | N/A | 5 | 3 up, 0 down | Mar 6, 2025 | $15.10M |
| Sep 30, 2024 | $0.06 | -$0.19 | -$0.58 - -$0.04 | +131.58% | Beat | N/A | 6 | 3 up, 0 down | Nov 8, 2024 | $11.20M |
| Jun 30, 2024 | -$0.48 | -$0.34 | -$0.42 - -$0.24 | -41.18% | Miss | N/A | 6 | 0 up, 0 down | Aug 5, 2024 | $7.77M |
| Mar 31, 2024 | -$0.45 | -$0.45 | -$0.61 - -$0.37 | 0.00% | In line | N/A | 4 | 0 up, 0 down | May 14, 2024 | $3.14M |
| Dec 31, 2023 | -$0.48 | -$0.51 | -$0.67 - -$0.41 | +5.88% | Beat | N/A | 5 | 0 up, 0 down | Mar 26, 2024 | $539000 |
| Sep 30, 2023 | -$1.14 | -$0.49 | -$0.63 - -$0.44 | -132.65% | Miss | N/A | 5 | 0 up, 0 down | Nov 13, 2023 | $434000 |
| Jun 30, 2023 | -$0.58 | -$0.66 | -$0.89 - -$0.44 | +12.12% | Beat | N/A | 3 | 1 up, 0 down | Aug 9, 2023 | $495000 |
| Mar 31, 2023 | -$0.77 | -$0.62 | -$0.90 - -$0.42 | -24.19% | Miss | N/A | 5 | 0 up, 1 down | May 22, 2023 | $597000 |
| Dec 31, 2022 | -$0.86 | -$0.73 | -$0.90 - -$0.46 | -17.81% | Miss | N/A | 5 | 0 up, 0 down | Mar 27, 2023 | $638000 |
| Sep 30, 2022 | -$0.92 | -$1.04 | -$1.16 - -$0.77 | +11.54% | Beat | N/A | 5 | 1 up, 0 down | Nov 8, 2022 | $906000 |
| Jun 30, 2022 | -$1.18 | -$1.01 | -$1.02 - -$0.89 | -16.83% | Miss | N/A | 4 | 0 up, 1 down | Aug 8, 2022 | $797000 |
| Mar 31, 2022 | -$1.00 | -$0.86 | -$0.95 - -$0.73 | -16.28% | Miss | N/A | 5 | 1 up, 0 down | May 10, 2022 | $378000 |
| Dec 31, 2021 | -$0.69 | -$1.01 | -$1.51 - -$0.72 | +31.68% | Beat | N/A | 5 | 0 up, 0 down | Mar 25, 2022 | $2.11M |
| Sep 30, 2021 | -$0.94 | -$1.13 | -$1.46 - -$0.91 | +16.81% | Beat | N/A | 4 | N/A | Nov 9, 2021 | $522000 |
| Jun 30, 2021 | -$0.96 | -$1.06 | -$1.15 - -$0.77 | +9.43% | Beat | N/A | 4 | N/A | Aug 10, 2021 | $536000 |
| Mar 31, 2021 | -$1.04 | -$1.03 | -$1.04 - -$0.89 | -0.97% | Miss | N/A | 2 | N/A | May 11, 2021 | $388000 |
| Dec 31, 2020 | -$0.60 | -$1.09 | -$1.39 - -$0.82 | +44.95% | Beat | -100.2% | 4 | N/A | Mar 31, 2021 | $507000 |
| Sep 30, 2020 | -$1.16 | -$2.11 | N/A | +45.02% | Beat | N/A | N/A | N/A | Nov 11, 2020 | $466000 |
| Jun 30, 2020 | -$1.90 | -$2.00 | N/A | +5.00% | Beat | N/A | N/A | N/A | Aug 13, 2020 | $379000 |
| Mar 31, 2020 | -$108.07 | -$108.07 | N/A | 0.00% | In line | N/A | N/A | N/A | May 14, 2020 | $294000 |
| Dec 31, 2019 | $269.30 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 25, 2020 | $518000 |
| Sep 30, 2019 | -$0.41 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2019 | $380000 |
| Jun 30, 2019 | -$0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jul 17, 2019 | $412000 |
| Mar 31, 2019 | -$0.11 | N/A | N/A | N/A | N/A | -101.0% | N/A | N/A | Jun 14, 2019 | $270000 |
| Dec 31, 2018 | -$0.17 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 13, 2019 | $1.02M |
| Sep 30, 2018 | -$0.25 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2018 | $824000 |
| Jun 30, 2018 | -$7.26 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 15, 2018 | $858000 |
| Mar 31, 2018 | $10.91 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 10, 2018 | $702000 |
| Dec 31, 2017 | -$380.17 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 16, 2018 | $704000 |
| Sep 30, 2017 | -$4,493.76 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2017 | $684000 |
| Jun 30, 2017 | -$1,347.43 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 8, 2017 | $584000 |
| Mar 31, 2017 | -$43,922.48 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 9, 2017 | $743000 |
| Dec 31, 2016 | -$1,000,000.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 29, 2017 | $676000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.07, a profit after a loss of $0.98 per share the year before. It was -$4,000,000.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.07 | N/A |
| Dec 31, 2024 | -$0.98 | N/A |
| Dec 31, 2023 | -$2.97 | N/A |
| Dec 31, 2022 | -$3.96 | N/A |
| Dec 31, 2021 | -$3.63 | N/A |
| Dec 31, 2020 | -$111.73 | -141.6% |
| Dec 31, 2019 | $268.70 | +8218.9% |
| Dec 31, 2018 | $3.23 | N/A |
| Dec 31, 2017 | -$50,143.84 | N/A |
| Dec 31, 2016 | -$4,000,000.00 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,200 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,207 | 10 | |
| 2026Q1 | Mar 31, 2026 | 4,739 | 12 | |
| 2025Q4 | Dec 31, 2025 | 5,787 | 11 | |
| 2025Q3 | Sep 30, 2025 | 4,029 | 12 | |
| 2025Q2 | Jun 30, 2025 | 5,877 | 13 | |
| 2025Q1 | Mar 31, 2025 | 5,798 | 12 | |
| 2024Q4 | Dec 31, 2024 | 6,271 | 13 | |
| 2024Q3 | Sep 30, 2024 | 5,475 | 12 |
2026Q3 Earnings Call
Opening remarks
David Hoffman General Counsel Thank you, and welcome to Delcath Systems' third quarter 2026 earnings call. With me on the call are Gerard Michel, Chief Executive Officer; Sandra Pennell, Chief Financial Officer; Kevin Muir, Chief Commercial Officer; Vojo Vukovic, Chief Medical Officer; and Martha Rook, Chief Operating Officer. This statement is made pursuant to the safe harbor for forward-looking statements described in the Private Securities Litigation Reform Act of 1995. The statements made on this call, with the exception of historical facts, may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the company believes that expectations and assumptions reflected in these forward-looking statements are reasonable, it makes no assurance that such expectations will prove to have been correct. Actual results may differ in a material manner from those expressed or implied in forward-looking statements due to various risks and uncertainties. For a discussion of such risks and uncertainties, please see the risk factors detailed in the company's annual report on Form 10-K, quarterly reports on Form 10-Q, and other reports that the company files from time to time with the Securities and Exchange Commission. Any forward-looking statements included in this call are made only as of the date of this call. We do not undertake any obligation to update or supplement any forward-looking statements to reflect subsequent knowledge, events, or circumstances. We will also discuss adjusted EBITDA, a non-GAAP financial measure. This measure should not be considered a substitute for GAAP results. A reconciliation to net income is included in our earnings release. The third quarter 2026 earnings release is available in the investor section of our website, along with additional details on our financial results and our latest SEC filings. We encourage you to review those materials. A recording of today's call will also be available on our website. Now I'll turn the call over to Gerard Michel. Gerard, please proceed.
Gerard Michel CEO Thank you, David, and good morning. Delcath's record third quarter of $35.1 million in revenue, up 71% in the third quarter of 2025, reflects the growing adoption of HEPZATO KIT and the hard work of both the Delcath and physician treatment teams. Just as importantly, we are delivering positive operating cash flow, which gives us the flexibility to support investment in both the treatment networks and ongoing research that will expand the platform. The growth and profitability were driven by strong new patient starts for the quarter at approximately 0.6 new patient starts per site per month. We now have 33 active treatment centers in the U.S. Since our last update, we have added the University of Nebraska and AdventHealth.
Frequently Asked Questions About DCTH
When is Delcath Systems's next earnings date?
Delcath Systems's next earnings report is expected for Feb 22, 2027.
Did DCTH beat earnings estimates last quarter?
Yes. Delcath Systems reported EPS of $0.17 for the quarter ended Sep 30, 2026, above the -$0.10 estimate, a 270.00% surprise.
What EPS do analysts expect from DCTH next quarter?
The consensus EPS estimate for Delcath Systems for the quarter ending Dec 31, 2026 is -$0.11 from 8 analysts, with estimates from -$0.18 to -$0.02.
How often does DCTH beat earnings estimates?
Delcath Systems beat the EPS estimate in each of the 8 most recent quarters that had an estimate, with an average surprise of +112.45%.
DCTH pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors